Gail Larkins

Phase 1 study of pomalidomide MTD, safety, and efficacy in patients with refractory multiple myeloma who have received lenalidomide and bortezomib

Paul G. Richardson, David S. Siegel, Rachid Baz et al. · Blood · 2012 · 161 citations · Full text

Medicine, Oncology, Pharmacology +15

Recognition of early mortality in multiple myeloma by a prediction matrix

Howard R. Terebelo, Shankar Srinivasan, Mohit Narang et al. · American Journal of Hematology · 2017 · 47 citations · Full text

Medicine, Hematology, Oncology +15

A Phase 1/2 Multi-Center, Randomized, Open Label Dose Escalation Study to Determine the Maximum Tolerated Dose, Safety, and Efficacy of Pomalidomide Alone or in Combination with Low-Dose Dexamethasone in Patients with Relapsed and Refractory Multiple Myeloma Who Have Received Prior Treatment That Includes Lenalidomide and Bortezomib.

Paul Richardson, David S. Siegel, Rachid Baz et al. · Blood · 2009 · 39 citations

Medicine, Pharmacology, Pharmacotherapy +15

Randomized, Open Label Phase 1/2 Study of Pomalidomide (POM) Alone or in Combination with Low-Dose Dexamethasone (LoDex) in Patients (Pts) with Relapsed and Refractory Multiple Myeloma Who Have Received Prior Treatment That Includes Lenalidomide (LEN) and Bortezomib (BORT): Phase 2 Results

Paul G. Richardson, David S. Siegel, Ravi Vij et al. · Blood · 2011 · 34 citations

Medicine, Oncology, Pharmacotherapy +13

Pomalidomide (POM) with or without low-dose dexamethasone (LoDEX) in patients (pts) with relapsed/refractory multiple myeloma (RRMM): Outcomes in pts refractory to lenalidomide (LEN) and/or bortezomib (BORT).

Ravi Vij, Paul G. Richardson, Sundar Jagannath et al. · Journal of Clinical Oncology · 2012 · 18 citations

Medicine, Pharmacology, Pharmacotherapy +15